Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

FDA cracks down on missing postmarket trial

June 22, 2018 11:16 PM UTC

FDA determined the Perrigo Israel Pharmaceuticals Ltd. unit of Perrigo Co. plc (NYSE:PRGO; Tel Aviv:PRGO) has failed to comply with a postmarketing trial requirement to assess the risk of major cardiovascular events (MACE) associated with its testosterone gel. As a result, the agency has determined that the testosterone replacement therapy product is misbranded, according to a June 15 letter released Friday.

FDA Commissioner Scott Gottlieb tweeted about the letter, making clear that it was intended as a warning to other companies that they must comply with postmarket trial commitments. “Postmarketing studies are important, providing additional evaluation after a drug is approved,” Gottlieb tweeted. “A company is responsible for adhering to the timetable for completing postmarketing studies.” ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Perrigo Co. plc